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Abstract
Introduction: Several biomarkers have been studied in febrile neutropenia. Our aim was to assess C-reactive
protein (CRP) concentration in septic critically ill cancer patients and to compare those with and without
neutropenia.
Methods: A secondary analysis of a matched case-control study conducted at an oncologic medical-surgical
intensive care unit (ICU) was performed, segregating patients with severe sepsis/septic shock. The impact of
neutropenia on CRP concentrations at admission and during the first week of ICU stay was assessed.
Results: A total of 154 critically ill septic cancer patients, 86 with neutropenia and 68 without, were included in the
present study. At ICU admission, the CRP concentration of neutropenic patients was significantly higher than in
non-neutropenic patients, 25.9 ± 11.2 mg/dL vs. 19.7 ± 11.4 mg/dL (P = 0.009). Among neutropenic patients, CRP
concentrations at ICU admission were not influenced by the severity of neutropenia (< 100/mm
3 vs. ≥ 100/mm
3
neutrophils), 25.1 ± 11.6 mg/dL vs. 26.9 ± 10.9 mg/dL (P = 0.527). Time dependent analysis of CRP from Day 1 to
Day 7 of antibiotic therapy showed an almost parallel decrease in both groups (P = 0.335), though CRP of
neutropenic patients was, on average, always higher in comparison to that of non-neutropenic patients.
Conclusions: In septic critically ill cancer patients CRP concentrations are more elevated in those with neutropenia.
However, the CRP course seems to be independent from the presence or absence of neutropenia.
Introduction
The frequency of cancer patients requiring intensive
care has increased dramatically over the last decades [1].
Frequently, in these patients, combined mechanisms of
immunosuppression coexist resulting in an increased
risk for sepsis. Infection is a feared and life-threatening
complication in cancer patients, in particular if neutro-
penia is present, that is frequently related to cancer
treatments, either radiation or chemotherapy [2].
Besides, the diagnosis of infection is often difficult since
the early symptoms and signs of sepsis, namely the sys-
temic inflammatory response syndrome (SIRS), can be
influenced by a number of non-infectious factors pre-
sent in hemato-oncological patients [3].
Fever is probably the most commonly used clinical
sign [4]. However, fever is not specific of infection since
some tumours as well as chemotherapy are characteristi-
cally associated with fever, and in addition steroids, used
in some cancer treatments, are very effective antipyretics
[5]. The white cell count (WCC) is also not very useful
since it can be markedly influenced by the cancer itself
as well as by the exposure to corticosteroids and
chemotherapy.
As a result early manifestations of infection are often
misleading, in particular in the presence of neutropenia.
Moreover, untreated infections in cancer patients can
rapidly lead to a fatal outcome but, treating non-infec-
tious causes with antimicrobials is ineffective, delays the
correct treatment of the underlying disease and also
increases costs, toxicity and the risk for the development
of bacterial resistance represent a serious complication
[6].
As a result of these limitations of the current clinical
and laboratory parameters in the prompt diagnosis of
infection, clinical research tried to identify mediators of
the inflammatory cascade [7], that might help in that
diagnosis. Several potential biomarkers of infection have
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patients, like interleukin (IL)-6, IL-8, serum amyloid A,
C-reactive protein (CRP), procalcitonin [8,9], with
diverse results.
Almost all studies assessed the diagnostic and/or prog-
nostic performance of different biomarkers of infection
in septic cancer patients, namely with febrile neutrope-
nia. However, non-neutropenic cancer patients with sep-
sis are usually excluded from these studies. In the
present study, our aim was to assess in septic cancer
patients the concentrations of a widely used biomarker
of infection, CRP, comparing the baseline concentrations
and response to antibiotic therapy in those with and
without neutropenia.
Materials and methods
Design and setting
The present study is a secondary analysis of a matched
case-control study performed in the ICU of Instituto
Nacional de Câncer (INCa), Rio de Janeiro, Brazil.
Details of the study design, definitions and data collec-
tion are provided elsewhere [10]. Briefly, during the
study period (January 2003 to July 2007), every adult
cancer patient (≥ 18 yrs) that required ICU admission
due to life-threatening complications was consecutively
enrolled. Patients in complete remission of more than 5
yrs, those with an ICU stay less than 24 hrs and read-
missions were not considered. The ICU is a 10-bed
medical-surgical unit specialized in the care of patients
with cancer [11,12], with the exception of bone marrow
transplant patients.
This study was supported by institutional funds and
did not interfere with clinical decisions related with
patient care. The Local Ethics Committee approved the
study (N° 10/2003) and the need for informed consent
was waived.
Definitions, selection of participants and data collection
Infection was defined as the presence of a pathogenic
microorganism in a sterile milieu (such as blood or cer-
ebrospinal fluid) and/or clinically suspected infection
that justified the administration of antibiotics [13,14].
Sepsis severity was classified according to the consensus
conference definitions [15].
Neutropenia was defined as a neutrophil count below
500/mm
3 [2]. Neutropenia was further classified as che-
motherapy related or unrelated. During the study per-
iod, from a prospective cohort of 1,332 consecutive
cancer patients, 94 patients with neutropenia and well-
matched controls without neutropenia, in a 1:1 ratio,
were compared [10]. For the present study, cancer
patients with sepsis were segregated, 86 neutropenic and
68 non-neutropenic. Empiric antibiotic therapy was
started in all septic cancer patients upon ICU admission
according to to local guidelines and in accordance with
the Infectious Diseases Society of America guidelines
[2]. The prescription was not delayed by the collection
of appropriate samples for microbiological cultures. At
least two blood cultures were performed from indepen-
dent venipunctures in each newly admitted patient.
Additional samples for microbiological cultures were
collected according to the suspected primary focus of
infection.
Demographic, clinical and laboratory data were col-
lected using standardized case report forms during the
first day of ICU stay including main diagnosis for admis-
sion, the Simplified Acute Physiology Score (SAPS) II
[16], the Sequential Organ Failure Assessment (SOFA)
score [17], comorbidities, and cancer- and treatment-
related data. For the purpose of the present study, indi-
vidual organ failures were diagnosed in case of a SOFA
score ≥ 2 points in each domain [14]. In addition,
patients receiving dialysis in the context of acute kidney
injury and invasive mechanical ventilation (MV) on the
first day of ICU were considered as having renal and
respiratory failures regardless the SOFA score, respec-
tively. The ICU and hospital mortality rates were also
assessed.
Blood samples were obtained via an arterial line on
admission and, subsequently, every morning at 07:00
hrs. Measurement of CRP was performed by means of
an immunoturbidimetric method using a commercially
available kit (Tina-quant CRP; Roche Diagnostics, Man-
nheim, Germany). The precision of the assay measured
by means of the intra- and inter-assay coefficient of var-
iation was < 7%, the sensitivity 0.1 mg/dL and the detec-
tion limit 0.3 mg/dL. C-reactive protein was measured
during the first week of ICU stay at Day 1 (D1), D3, D5
and D7.
CRP concentrations at ICU admission and during the
first week of sepsis course were analysed, comparing
neutropenic with non-neutropenic septic critically ill
cancer patients.
Data processing and statistical analysis
Data entry was performed by a single investigator (MS)
and consistency was assessed with a rechecking proce-
dure of a 10% random sample of patients. Data were
screened in detail by three investigators (MS, JIFS,
VCSD) for missing information, implausible and outly-
ing values.
Continuous variables were reported as mean ± stan-
dard deviation or median (25% to 75% interquartile
range, IQR) according to data distribution. Comparisons
between groups were performed using the parametric
unpaired and paired t-test, or the nonparametric Mann-
Whitney U test and Wilcoxon signed-rank test for con-
tinuous variables according to data distribution. The
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between categorical variables. Correlations were calcu-
lated by the Spearman’s rank correlation. Time-depen-
dent analysis of CRP was performed via General Linear
Model univariate repeated-measures analysis using a
split-plot design approach.
In all cases, statistical significance was defined as a
two-tailed test with an alpha of 0.05. All statistical cal-
culations were preformed using the PASW v. 18.0 for
MAC (SPSS, Chicago, IL, USA).
Results
Characteristics of the study population
A total of 154 critically ill septic cancer patients were
included in the present study, 86 with neutropenia,
that represents all neutropenic septic cancer patients
admitted in the ICU during the study period, and the
remainder without neutropenia (N = 68). The patients’
main characteristics are depicted in Table 1. The
sources of ICU admission were the operating room
(10.4%), emergency department (16.9%) and wards
(72.7%) (P = 0.238, comparing neutropenic vs. non-
neutropenic patients). There were 105 (68.2%) patients
with hematological malignancies and 49 (31.8%) with
solid tumors (P = 0.569). The most frequent underly-
ing malignancies were lymphomas (N = 59, 38.3%),
leukemias (N = 32, 20.8%), gastrointestinal (N = 13,
8.4%), multiple myeloma (N =9 ,5 . 8 % ) ,u r o g e n i t a l( N =
8, 5.2%) and others (N =3 3 ,2 1 . 4 % ) .P r e v i o u sa n t i c a n -
cer treatments included surgery for tumor resections
(3.9%), chemotherapy (72.7%) and radiation therapy
(23.4%). Comorbidities were indentified in 129 (83.8%)
patients and the most frequent were immunosuppres-
sion (40.3%), arterial hypertension (20.4%), acquired
immunodeficiency syndrome (8.4%), diabetes mellitus
(6.5%) and chronic obstructive pulmonary disease
(6.5%).
The length of ICU and hospital stay were (median
(IQR)) 7.0 (10.3) days and 18.5 (23.6) days, respectively,
without significant differences between neutropenic and
non-neutropenic patients (P =0 . 6 9 9a n dP =0 . 1 1 1 ,
respectively). The overall ICU and hospital mortality
rates were 72.1% and 79.2%, respectively, without signifi-
cant differences between study groups (P =0 . 4 7 2a n dP
= 0.211, respectively).
Most of the patients were admitted in the ICU in
severe sepsis/septic shock (93.5%) as well as with a
severe degree of organ failure/dysfunction (SOFA at D1,
11.4 ± 3.9 points).
Almost two-thirds of the infections were microbiologi-
cally proven infections (65.1%). As expected, the most
frequent sites of infection were the lungs, abdomen and
bloodstream infection. Gram-negative bacteria were
responsible for 72.2% of the infection episodes and 26
(36.6%) patients had polymicrobial (more than one
infectious agent) infections.
Impact of neutropenia on temperature and C-reactive
protein
At ICU admission, temperature in septic critically ill
cancer patients was not significantly different in those
presenting neutropenia in comparison with non-neutro-
penic patients (37.2 ± 1.5°C vs. 36.8 ± 1.5°C, respec-
tively, P = 0.119) (Figure 1). Concerning CRP (Figure 1),
we found that neutropenic septic cancer patients
showed a significantly higher concentration, 25.9 ± 11.2
mg/dL, in comparison with CRP concentration from
non-neutropenic patients, 19.7 ± 11.4 mg/dL (P =
0.009). Additionally, among neutropenic patients CRP
concentrations at ICU admission were not influenced by
the severity of neutropenia (< 100/mm
3 vs. ≥ 100/mm
3
neutrophils), 25.1 ± 11.6 mg/dL vs. 26.9 ± 10.9 mg/dL,
respectively (P = 0.527).
We also assessed the correlation between WCC and
CRP concentration. We found a poor, whilst significant,
correlation between these two variables (rs = -0.252, P =
0.012).
C-reactive protein course in neutropenic and non-
neutropenic patients
Time dependent analysis of CRP (Figure 2) from D1 to
D7 of antibiotic therapy showed an almost parallel
course in both groups (P = 0.335), with almost no
change from D1 to D3, followed by a significant
decrease from D3 onwards; though the CRP concentra-
tion of neutropenic patients was, on average, higher in
comparison to that of non-neutropenic patients. From
D1 to D7, CRP concentration of neutropenic and non-
neutropenic patients decreased from 25.9 ± 11.2 mg/dL
and 19.7 ± 11.4 mg/dL at D1 to 14.1 ± 9.1 mg/dL and
13.1 ± 10.8 mg/dL at D7 (P <0 . 0 0 1a n dP =0 . 0 0 9 ,
respectively).
Discussion
We found among septic critically ill cancer patients a
marked increase in CRP concentrations irrespective of
the WCC, at ICU admission. Even though CRP concen-
trations in neutropenic patients were significantly
higher, we found a poor correlation between WCC and
CRP concentrations. Finally, our findings demonstrate
that the course of CRP during the first week of antibio-
tic therapy was similar in neutropenic and non-neutro-
penic septic critically ill cancer patients.
Since inadequately treated infections can be rapidly
fatal in neutropenic cancer patients, a great deal of clini-
cal research on biomarkers has been published [8,9].
Several biomarkers, such as IL-6, IL-8, CRP, brain
natriuretic peptides, procalcitonin, neopterin, have been
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their performance in the diagnosis of infection [18-24],
in the identification of the underlying agents
[18-20,22,24], in the characterization of sepsis severity
and outcome prediction [21,23-27]. However, informa-
tion on biomarkers comparing neutropenic and non-
neutropenic cancer patients are currently limited [28].
Among septic non-cancer patients there is substantial
controversy concerning the potential effects of immuno-
suppression, in particular of corticosteroids, on CRP
concentration, decreasing acute phase response indepen-
dently of the treatment of infection [29-33].
In the present study, we clearly demonstrate that CRP,
a major acute phase reactant protein, increases markedly
in profoundly immunosuppressed cancer patients with
sepsis. In other words, the acute phase reaction seems
to remain unaffected by either chemotherapy or radio-
therapy. Moreover, we found that septic neutropenic
cancer patients had significantly higher CRP concentra-
tions in comparison with non-neutropenic patients at
ICU admission. Neutropenia reflects a profound state of
immunosuppression representing a markedly increase
susceptibility to infections [4]. In addition, neutropenic
patients present an increased risk to acquire infections
caused not only by “common” bacteria, but also by
opportunistic agents, like virus and fungi, secondary to a
decrease cellular and humoral immunity [4]. In addition,
the size of the inoculum necessary to produce an
Table 1 Baseline patients’ characteristics and comparison between neutropenic and non-neutropenic patients
All Patients Neutropenic Non neutropenic P-value
N 154 86 68
Age (yrs) 48.5 ± 18.1 47.0 ± 17.8 50.4 ± 18.4 0.248
Gender (M/F) 94/60 54/32 40/28 0.622
Type of cancer 0.569
Solid 49 29 20
Hematologic 105 57 48
Previous radiotherapy 36 21 15 0.731
Previous Chemotherapy 112 72 40 0.001
Previous surgery 6 1 5 0.049
Non-invasive Ventilation 15 14 1 0.002
Invasive mechanical Ventilation 135 74 61 0.493
Vasopressors 112 62 50 0.842
Type of infection 0.007
Pneumonia 63 28 35
Peritonitis 15 7 8
Urinary 3 0 3
Blood stream infections 8 4 4
Skin/Soft tissue infections 7 4 3
CNS infections 1 0 1
Other infections 57 43 14
SAPS II (points) 62.2 ± 16.8 62.2 ± 16.7 62.5 ± 16.8 0.827
SOFA (Day 1) (points) 11.4 ± 3.9 11.6 ± 4.1 11.2 ± 4.1 0.591
Sepsis severity 0.899
Sepsis 10 (6.5%) 6 (7%) 4 (5.9%)
Severe sepsis 29 (18.8%) 17 (19.8%) 12 (17.6%)
Septic shock 111 (74.7%) 63 (73.3%) 52(76.5%)
Total white cell count (/mm
3) 1,400 (14,636) 352 (909) 22,100 (35,900) < 0.001
Temperature (°C) 37.0 ± 1.5 37.2 ± 1.5 36.8 ± 1.5 0.119
CRP (Day 1) (mg/dL) 23.6 ± 11.6 25.9 ± 11.2 19.7 ± 11.4 0.009
Duration of mechanical ventilation (days) 6.0 (9.0) 6.0 (8.0) 6.0 (9.0) 0.616
ICU length of stay (days) 7.0 (10.3) 7.0 (12.0) 8.0 (10.0) 0.699
Hospital length of stay (days) 18.5 (23.6) 20.5 (25.0) 16.5 (21.0) 0.111
ICU mortality 111 (72.1%) 60 (69.8%) 51 (75.0%) 0.472
Hospital mortality 122 (79.2%) 65 (75.6%) 57 (83.8%) 0.211
Values expressed as N (%), mean ± standard deviation or median (interquartile range] according to type of data and data distribution; abbreviations: CNS, central
nervous system; CRP, C-reactive protein; ICU, intensive care unit; SAPS II, Simplified Acute Physiology Score II; SOFA, Sequential Organ Failure Assessment score
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text, we could hypothesize that microbiological agents
would invade and proliferate easily in neutropenic
patients, reaching a higher microbiological burden and
also leading to a larger inflammatory response, reflected
by a higher CRP concentration [34-36].
Consequently, our findings pointed to the clinical use-
fulness of CRP in critically ill septic cancer patients irre-
spective of the presence or absence of neutropenia, as
well as, the degree of neutropenia.
Interestingly, other commonly used biomarkers in
non-cancer patients, such as PCT, should be used with
some reserve in neutropenia. The origin of PCT in the
inflammatory response is not yet fully understood [37].
Moreover, it has been shown that in septic cancer
patients with leukopenia PCT concentrations were lower
when compared with patients without leukopenia [28].
Consequently, it is possible to observe PCT values < 0.5
ng/ml in infected febrile neutropenic patients [9].
Besides, we recognize that the present study has some
limitations. First, our study was an observational single
centre study. Second, clinical and laboratory data asses-
sing the recovery phase of neutropenia and factors that
could have influenced the CRP course were not routi-
nely collected. Third, since we only assessed CRP course
during the first week of antibiotic therapy we cannot
draw any conclusion concerning CRP course beyond
D7. However, our study has also several important
strengths. To date, this is the first study comparing CRP
concentrations in septic cancer patients with and with-
out neutropenia, and with a large cohort of septic neu-
tropenic patients.
Conclusions
In conclusion, the results of this study provide valuable
information concerning the CRP biology and time-
course in septic critically ill cancer patients. It was clear
from our results that septic cancer patients express a
full blown acute phase response with marked CRP eleva-
tions, and that this was particularly significant in the
presence of neutropenia. Finally, CRP course was not
influenced by the presence or absence of neutropenia.
As a result, CRP could be a clinically useful bedside bio-
marker of infection in cancer patients irrespective of the
WCC and the degree of immunosuppression.
αͲǤͳͳͻ
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Figure 1 Temperature and C-reactive protein of neutropenic
and non-neutropenic septic cancer patients at ICU admission.
Comparison of temperature (°C) and C-reactive protein
concentrations (mg/dL) at ICU admission between neutropenic and
non-neutropenic septic critically ill cancer patients (P = 0.119 and P
= 0.009, respectively).
αͲǤ͵͵ͷ
Figure 2 C-reactive protein course of neutropenic and non-
neutropenic septic critically ill cancer patients. Time course of
CRP concentrations (mg/dL) for neutropenic and non-neutropenic
septic critically ill cancer patients during the first week of antibiotic
therapy (P = 0.335).
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￿ In the present study we showed that septic cancer
patients express a full blown acute phase response with
marked CRP elevations, and that this was particularly
significant in the presence of neutropenia.
￿ The CRP course during the first week of antibiotic
therapy was not influenced by the presence or absence
of neutropenia.
￿ CRP could be a useful biomarker of infection in can-
cer patients irrespective of the WCC and the degree of
immunosuppression.
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